RECORD // Company

Viking Therapeutics, Inc.

Built 2026-11-21T23:58:31Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Viking Therapeutics, Inc. · Ctgov · same registered legal name as 'Viking Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • VIKING THERAPEUTICS, INC. · Ny corps · same registered legal name as 'Viking Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-10-29 · accession 0001193125-26-436432

ItemValuePeriodFormFiledAccessionReport
Revenue$03 months ended 2026-09-3010-Q2026-10-290001193125-26-4364322026-11-21 23:58 UTCReport an error
Net income (loss)$-183,186,0003 months ended 2026-09-3010-Q2026-10-290001193125-26-4364322026-11-21 23:58 UTCReport an error
Interest expense$88,0003 months ended 2026-09-3010-Q2026-10-290001193125-26-4364322026-11-21 23:58 UTCReport an error
Cash and cash equivalents$677,609,000at 2026-09-3010-Q2026-10-290001193125-26-4364322026-11-21 23:58 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001607678
Ticker
VKTX
EIN
461073877
CUSIP
92686J106
Record ID
sx:sec:0001607678

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

33 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-05SEC EDGAR company profile2026-11-21 23:58 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-05SEC EDGAR company profile2026-11-21 23:58 UTCReport an error
State of incorporationDE2026-11-05SEC EDGAR company profile2026-11-21 23:58 UTCReport an error
Fiscal year end (MMDD)12312026-11-05SEC EDGAR company profile2026-11-21 23:58 UTCReport an error
Business address9920 PACIFIC HEIGHTS BLVD, SUITE 500, SAN DIEGO, CA2026-11-05SEC EDGAR company profile2026-11-21 23:58 UTCReport an error
ExchangesNasdaq2026-11-05SEC EDGAR company profile2026-11-21 23:58 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$02025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 23:58 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-359,639,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 23:58 UTCReport an error
Total assets (at 2025-12-31)$715,729,0002025-12-3110-K, XBRL Assets2026-11-21 23:58 UTCReport an error
Stockholders' equity (at 2025-12-31)$639,062,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 23:58 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$165,810,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 23:58 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-278,685,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 23:58 UTCReport an error
Operating lease liabilities (at 2025-12-31)$137,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 23:58 UTCReport an error
Form D total offering amount (D filed 2017-06-22)$3,656,0382017-06-22D2026-11-21 23:58 UTCReport an error
Form D total amount sold (D filed 2017-06-22)$02017-06-22D2026-11-21 23:58 UTCReport an error
Form D industry groupBiotechnology2017-06-22D2026-11-21 23:58 UTCReport an error
Form D revenue rangeNo Revenues2017-06-22D2026-11-21 23:58 UTCReport an error
Form D date of first sale2017-06-192017-06-22D2026-11-21 23:58 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-10-28)On October 28, 2026, we issued a press release reporting our financial results for the third quarter ended September 30, 2026 and providing a corporate update. The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed…2026-10-28SEC EDGAR 8-K 0001193125-26-436145 (text as filed, excerpt)2026-11-21 23:58 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-09-28)Equity Offering On September 23, 2026, Viking Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Equity Underwriting Agreement”) with Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC (the “Equity Representatives”), as representatives of the several underwriters named therein (the “Equity Underwriters”), to issue and sell (the “Equity Offering”) 7,857,143 shares of the Company’s common stock, par value $0.00001 per share (“Common Stock”), at a public offering price of $35.00 per share. Under the terms of the Equity Underwriting Agreement, the Company also granted the Equity Underwriters a 30-day option to purchase up to an additional 1,178,571 shares of…2026-09-28SEC EDGAR 8-K 0001193125-26-405580 (text as filed, excerpt)2026-11-21 23:58 UTCReport an error
8-K Item 2.03, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (filed 2026-09-28)The information set forth under the heading “Debt Offering” in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve risks and uncertainties, such as statements related to the estimated offering expenses of, and anticipated use of proceeds from, the Equity Offering and Debt Offering. The risks and uncertainties involved include those detailed in the final prospectus supplements for the offerings and from time to time in the Company’s periodic reports and other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements…2026-09-28SEC EDGAR 8-K 0001193125-26-405580 (text as filed, excerpt)2026-11-21 23:58 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-09-22)On September 22, 2026, Viking Therapeutics, Inc. issued a press release announcing top-line results from its maintenance study of GLP-1/GIP agonist VK2735. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.2026-09-22SEC EDGAR 8-K 0001193125-26-397219 (text as filed, excerpt)2026-11-21 23:58 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-07-29)On July 29, 2026, we issued a press release reporting our financial results for the second quarter ended June 30, 2026 and providing a corporate update. The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under…2026-07-29SEC EDGAR 8-K 0001193125-26-323652 (text as filed, excerpt)2026-11-21 23:58 UTCReport an error
Largest institutional holder #1 (13F as filed): FMR LLC$247,157,8302026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #2 (13F as filed): BlackRock, Inc.$241,458,2132026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #3 (13F as filed): STATE STREET CORP$218,705,4302026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #4 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$197,143,3942026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #5 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$174,931,1002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #6 (13F as filed): TWO SIGMA INVESTMENTS, LP$153,598,5202026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #7 (13F as filed): AMERIPRISE FINANCIAL INC$84,108,7972026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #8 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$81,865,3602026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #9 (13F as filed): AMERICAN CENTURY COMPANIES INC$70,844,1862026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error
Largest institutional holder #10 (13F as filed): D. E. Shaw & Co., Inc.$62,649,8262026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:58 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.